Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/759"

Predicate	Value (sorted: none)
rdf:type	?:Evidence
rdf:type	?:Item
rdfs:label	"evidence_1414"
?:Evidence_type	?:EV_PK_DDI_RCT
?:Evidence_assump_list_id	"145"
?:Evidence_enzyme_system	""
?:claim_assumed_valid_for_evidence_application_evidence_1414	?:midazolam_primary_total_clearance_enzyme_cyp3a4
dc:creator	"boycer"
dc:date	"05/21/2007 15:27:20"
?:content	"Route of administration: oral polymorphic enzyme: NO study duration: 12 days population: 17 male, 23 female ages:18-50 description: Forty healthy subjects were randomized to receive one of the four study drugs for 12 days in a parallel study design: fluoxetine 60 mg per day for 5 days, followed by 20 mg per day for 7 days; fluvoxamine titrated to a daily dose of 200 mg; nefazodone titrated to a daily dose of 400 mg; or ketoconazole 200 mg per day. All 40 subjects received oral midazolam solution before and after the 12-day study drug regimen. Blood samples for determination of midazolam concentrations were drawn for 24 hours after each midazolam dose and used for the calculation of pharmacokinetic parameters. The effects of the study drugs on midazolam pharmacodynamics were assessed using the symbol digit modalities test (SDMT). The mean area under the curve (AUC) for midazolam was increased 771.9% by ketoconazole..."
rdfs:seeAlso	?:14551182

The resource appears as object in one triple:

{ ketoconazole_inhibits_cyp3a4, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1414 }

Context graph